GlassScriptPhysician profile
Quentin S Dickins
NPI 1154430957
$732.81
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $100.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $273.20 | 2019-2020 | |
| Lilly USA, LLC | $90.75 | 2019 | |
| Amgen INC. | $48.02 | 2019 | |
| Biogen, INC. | $43.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $42.64 | 2019 | |
| Eisai INC. | $41.32 | 2019 | |
| Harmony Biosciences LLC | $39.12 | 2020 | |
| Genzyme Corporation | $29.08 | 2019 | |
| Amneal Pharmaceuticals LLC | $26.58 | 2019 | |
| Allergan, INC. | $16.62 | 2020 | |
| Neurocrine Biosciences, INC. | $14.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.63 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.18 | 2019 | |
| Adamas Pharmaceuticals, INC. | $13.71 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.77 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quentin Dickins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.